Curis Q1 net loss $10.6M, appoints Dr. Hamdy CMO, emavusertib progress

CURIS INC

2025-Q1 EPS reported -$1.25 revenue$2,380,000

Net loss $10.6M ($1.25/share); cash $20.3M; runway into Q4 2025.
Revenue $2.4M from Genentech/Roche Erivedge royalties.
Appointed Dr. Ahmed Hamdy (ex-Pharmacyclics, Acerta) as CMO.
FDA & EMA meetings support accelerated approval path for emavusertib in PCNSL.
Completed registered direct offering and private placement with net proceeds ~$8.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.